Introduction
Epstein-Barr virus (EBV), an ubiquitous human herpes virus which causes infectious mononucleosis, is closely associated with two human cancers: Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC) (Klein, 1973; De TheÂ , 1982; Ooka and Sixbey, 1991) . Almost all endemic BL and NPC biopsies contain EBV genome. A particular feature of EBV is its ability to infect in vitro resting B lymphocytes, leading to their immortalization (Kie, 1996; Rickinson and Kie, 1996) . At least six latent genes are identi®ed as essential for B cell immortalization: ®ve nuclear proteins (EBNA1, EBNA2, EBNA3A, EBNA3C and EBNA-LP) and LMP1 (Mannick et al., 1991; Tomkinson et al., 1993; Kie, 1996) .
Concerning the epithelial cell malignancy induced by EBV, we showed previously that the introduction of EBV early BARF1 gene in the primary monkey epithelial cells led to their immortalization . Since expression of BARF1 was detected with a high proportion in EBV-positive gastric and NPC tumors (Decaussin et al., 2000; Hayes et al., 1999; zur Hausen et al., 2000) , this gene may play an important role in epithelial cell malignancy.
Among more than 90 genes encoded by EBV (Baer et al., 1984) , two viral proteins, LMP1 and p31 encoded by BARF1 gene (called p31), were known to induce a malignant transformation in established rodent cells (Wang et al., 1985; Baichwal and Sugden, 1988; Wei and Ooka, 1989) . N-terminal transmembrane domain including exons 1 to IV of LMP1 protein is involved in the induction of malignant transformation in Rat-1 and Balb/c3T3 cells (Wang et al., 1985; Baichwal and Sugden, 1989) , while its CTAR1 and CTAR2 domains in C-terminal region is rather implicated in B cell immortalization (Mosialos et al., 1995; Huen et al., 1995; Mitchel and Sugden, 1995; Kaye et al., 1993; . LMP1 therefore possess two distinct cell type dependent oncogenic domains in its own protein. The other rodent cell transforming gene BARF1 encodes a 31 kDa protein which was recognized by NPC sera as having a high EA (Early Antigen) titer (Zhang et al., 1988; Wei and Ooka, 1989; De Turenne-Tessier et al., 1997) . The expression of BARF1 is not inhibited in the presence of viral DNA replication inhibitors like phosphonoacetic acid (Zhang et al., 1988) and arabinofuranosylthymine (araT) (Ooka and Calender, 1980; Ooka et al., 1983) , suggesting BARF1 gene as an EBV early gene. The p31 has an oncogenic activity susceptible to induce a malignant transformation in Balb/c3T3 cell line as well as in an EBV negative human Louckes B cell line, inducing a tumor in new-born rats (Wei and Ooka, 1989; Wei et al., 1994) . Its additional oncogenic activity is to immortalize in vitro simian primary epithelial cells . Recent studies showed that BARF1 protein became a target of NK (Natural Killer) cells in ADCC (Antibody Dependent Cell Cytotoxicity) assays (Tanner et al., 1997) . It might also function as a receptor for the human colony-stimulating factor (hCSF-1) (Stockbine et al., 1998) and as an inhibitor of alpha interferon secretion in B cells (Cohen and Lekstrom, 1999) , suggesting that BARF1 biological activity likely concerns both immunomodulation and oncogenicity.
Since BARF1 was capable of inducing a malignant transformation in established rodent cells, this system constitutes a good model for studying the mechanism of its malignant transforming activity. Studies realized on the molecular basis for multi-step transformation have demonstrated that at least a part of this process comes from the cooperative action of several oncogenes (Land et al., 1983) . These cooperations may occur during the evolution of a cell from the benign to the malignant state (Land et al., 1983; Reed et al., 1990; Hahn et al., 1999) . It is quite possible that BARF1 is cooperated with some cellular oncogenes to evolve Balb/c3T3 towards the malignant state. However we do not know which region(s) of BARF1 gene is(are) responsible for inducing a malignant transformation in rodent cells, nor which cellular protein(s) is(are) involved in the evolution of Balb/c3T3 cells to the malignant state. Our question was therefore addressed ®rst to know which domaine(s) of BARF1 protein is(are) involved in the induction of a malignant transformation and second, to know which cellular proteins are associated with malignant transformation induced by BARF1. Six deletion mutants were constructed and transfected in Balb/c3T3 cell line. The transfectants were assayed for the capacity on agarose medium, serum dependence, and for tumorigenicity in nude mice. These experiments identify BARF1 domains essential for rodent cell transformation. Surprisingly, the transforming region identi®ed here is responsible for the activation of Bcl-2 expression.
Results

Construction of deletion mutants and their expression in Balb/c3T3
The BARF1 protein is composed of 221 amino acids (Figure 1 ). BARF1-predicted polypeptide analysis indicates that BARF1 protein has a peptide signal at residue 20, three myristylation sites at residue 18, 26 and 212, a N-glycosylation site at residue 95, cAMP/ cGMP-dependent kinase phosphorylation sites at residue 39, Protein kinase C phosphorylation sites at residue 131 and casein kinase II phosphorylation at residue 114. Six deletion mutants, called MD1, MD2, MD3, MD4, MD5 and MD6, were constructed using a PCR method: MD1 deleted codons 1 to 26, MD2 deleted codons 1 to 54, MD3 deleted codons 88 to 173, MD4 deleted codons 50 to 120, MD5 deleted codons 170 to 221 and MD6 deleted codons 56 to 221. All deleted mutants were sequenced in order to verify eventual existence of nucleotide mutations caused by PCR method. No mutations were found for all deletion mutant sequence. The deletion mutants as well as a full-length of BARF1 sequence were then inserted into pZip-Neo-SV(X) retroviral expression vector (Cepko et al., 1984; Wei and Ooka, 1989) .
After transfection of these mutants in Balb/c3T3 cells, several numbers of neo-resistant colonies were isolated. The expression of each mutant was examined by RT ± PCR method. After RNA extraction from each mutant, cDNA was synthesized and ampli®ed by Taq polymerase using the primers as described in Materials and methods. Ampli®ed cDNA sequence was electrophoresed, transferred onto Hybond ®lter and hybridized with a full-length of BARF1 sequence. Autoradiogram was presented in Figure 2 . The size of ampli®ed cDNA product from pZC55 transfectant (a full-length of BARF1 gene: 668 bp) corresponds to that of TPA-SB-treated P3HR-1 cells in which early gene like BARF1 was expressed. All transfectants from the deletion mutants gave a positive signal with homogeneous intensity and gave an expected 
Growth in soft agar
Anchorage independence property in ®broblastic cells transfected by BARF1 gene was reported previously (Wei and Ooka, 1989) . To determine whether these deletion mutants have transforming activity, the cell growth capacity was examined in 0.33% agar. 0.5610 6 cells of each transfectant were seeded in a 100-mm petri- (Pearson and Lipman, 1988) and NCBI BLAST service (Altschul et al., 1990) . Possible modi®cation sites at the following residues: a: Signal peptide cleavage; b: myristylation; c: myristylation; d: myristylation; e: N-glycosylation; f: cAMP-and cGMP-dependent protein kinase site; g: protein kinase C site; h: casein kinase II site. In under part, each conserved amino acid sequence of deletion mutants was indicated as solid bars. Deleted amino acid sequences are 2 ± 26 a.a., 2 ± 54 a.a., 88 ± 173 a.a., 50 ± 120 a.a., 170 ± 221 a.a. and 56 ± 221 a.a. for MD1, MD2, MD3, MD4, MD5 and MD6, respectively Oncogene A malignant transformation domain of BARF1 gene W Sheng et al dish with 0.33% of agar. Colony formation was then checked after three weeks. Colony formation in soft agar is presented in Figure 3 and summarized in Table  1 . Cloning eciency is represented by the number of colonies with 4200 cells per heap in a 100-mm petri dish. pZC55 formed about 205 colonies per petri dish (average of value obtained from three subclones), while Balb/c3T3 or Balb/c3T3 transfected with vector alone did not give any positive colony. Concerned deletion mutants, MD3, MD4 and MD5 formed similar number of colonies as that of pZC55. By contrast, MD1 and MD2 did not give large heap, but gave a smaller colony with few cells and no cloning eciency with 4200 was observed. MD1 (lacking codons 1 to 26) gave 20 colonies per petri-dish containing 10 ± 20 cells per heap and MD2 (lacking codons 1 to 54) with 50 colonies per petri-dish containing 2 ± 4 cells per heap. In regard to the capacity to develop the tumor with MD4 (deletion codons 50 ± 120) (see next section), the N-terminal of BARF1 protein codons 1 to 49 amino acids is likely essential to induce a transforming activity. When we examined the transforming activity of MD6 recombinant (lacking codons 56 ± 221), MD6 transfectants gave about 159 colonies containing 4200 cells per petri dish as those obtained with pZC55, MD3, MD4 and MD5 transfectants.
Tumorigenicity assays in nude mice
The above results suggest that the N-terminal codons 1 to 54 of BARF1 protein are essential for transforming Figure 2 Detection of transcriptional expression of BARF1 and its deletion mutants by RT-PCR. Total RNA was extracted from each transfectants. After treatment with DNase 1, cDNA was synthesized from RNA and ampli®ed with PCR using the primers as described in Materials and methods. PCR products were analysed by Southern blot using BARF1 speci®c probe. P3HR-1 induced by TPA ± BA was used as a positive control. Balb/c3T3 and pZip vector transfected cells were used as negative controls. The sizes of the ampli®ed fragments were 668 bp for pZC55, 593 bp for MD1, 509 bp for MD2, 416 bp for MD3, 461 bp for MD4, 518 bp for MD5 and 176 bp for MD6, respectively Figure 3 Soft-agar assays. Anchorage dependence of cell growth was tested in 0.33% agarose in DMEM medium with 10% fetal calf serum. 0.5610 6 cells suspended in 4 ml complete DMEM medium containing 0.33% agarose were layered onto 0.66% agarose. Cultures were fed with complete DMEM medium twice a week. The colonies were photographed after 4 weeks activity. We therefore examined whether these regions have a capacity to induce a tumor in nude mice. Tumorigenicity of deletion mutants was initially assayed by injection of 10610 6 cells per animal in nude mice. Culture medium without serum, Balb/c3T3 cells and pZip-Neo-SV(X) carrying Balb/c3T3 cells were used as negative controls and HeLa cells as a positive control. Table 2 illustrates tumor formation in nude mice. No tumor was observed with negative controls, 0/6 mice for Balb/c3T3 and 0/8 mice for pZip-Balb/c3T3. Injection of HeLa cells (2/2 mice) and Balb/c3T3 carrying a full-length of BARF1 sequence (12/12 mice) induced a progressively enlarged tumor at the site of inoculation. For the deletion mutants, MD3 (12/12 mice), MD4 (12/12 mice) and MD5 (12/12 mice) formed the tumor like those of positive controls, while only three of 12 mice for MD1 formed the tumor after three weeks and none of 12 mice for MD2 formed the tumor. The tumor induced in MD1 was much smaller than those of other mutants MD3, MD4 and MD5. Both MD3 and MD5 began to form the tumor after 10 days of innoculation, while MD4 developed the tumor as early as 7 days. At 3 weeks, the size of tumor is more important for positive control HeLa and pZC55 transfectant (2.763.5 cm) than those of MD3 and MD5 (1.662.1 cm). MD4 gave more important tumor (2.462.9 cm) than MD3 and MD5. In order to analyse whether MD6 containing only a region (codons 1 to 56) which is deleted in MD1 and MD2 is able to induce the tumor, we injected MD6 carrying Balb/c3T3 in nude mice. Sixteen of 16 mice developed the tumor like pZC55 and other deletion mutants (MD3, MD4 and MD5), but the size of tumor was somehow smaller than those of other tumorigenic deletion mutants.
Characteristics of Balb/c3T3 carrying deletion mutants BARF1 gene carrying Balb/c3T3 cell clones grew much higher cell density than Balb/c3T3 transfected pZipNeo-SV(X) vector alone (Wei and Ooka, 1989) . MD1 and MD2 failed to grow on soft agar and particularly MD2 did not induce any tumor in nude mice. To test whether or not MD1 and MD2 transfectants can grow at a higher cell density, we examined their cell growth rate in 10% serum concentration (normal serum concentration). All transfectants were seeded in four 100-mm petri-dishes with 0.5610 6 cells per dish in DMEM medium with 10% fetal calf serum and cultured. After 24 h, culture mediums were changed with medium containing 10% serum. Culture medium was renewed every 4 days and one of four petri-dishes was trypsinized at time indicated in Figure 4 and We then examined cell growth of each transfectant with two other serum concentrations (1 and 0.1%). For this, after 24 h of cell culture with 10% serum, culture medium was removed and cultures were washed three times with DMEM medium without serum. Then a complete medium with either 1 or 0.1% of serum was added and the cells were cultured 16 days with a change of medium every 4 days. At 1% of serum (Figure 4b) , pZC55, MD3, MD4, MD5 and MD6 cells were capable of growing, but with about 50% reduced rate after 4 days in comparison with those with 10% serum. Then the cell numbers began to increase progressively with time and reached 15 ± 28610 6 cells after 16 days (Figure 4b , right side). By contrast, MD1 and MD2 as well as the controls pZip-Balb/c3T3 and Balb/c3T3 grew at about 20 ± 50% reduced growth in comparison with those with 10% serum during 4 days. After this period, these cells entered in apoptosis, decreasing progressively viable cell numbers. Only a few live cells were found after 16 days (Figure 4b , left side). At 0.1% serum (Figure 4c ), no signi®cant cell growth was observed for 16 days for Balb/c3T3, pZipBalb/c3T3, MD1 and MD2 and no live cells were found at 16 days. A slight increase of cell numbers was registered in MD3, MD4, MD5 and pZC55 during 4 days and about 3.1 ± 4.4610 6 MD3, MD4, MD5, MD6 and BARF1 transfectant cells were still alive at 16th day ( Figure 4c, right side) . Taking all together, we can conclude that pZC55, MD3, MD4, MD5 and MD6 transfectant cells could escape from apoptosis induced by serum deprivation.
Analysis of c-myc and bcl-2 expression
Distinct phenotypes observed in serum deprivation assay suggested that BARF1 gene renders cells resistant to apoptosis. We were therefore interested to examine whether the above dierences were re¯ected in deregulation of some cellular proteins involved in apoptosis (Vaux, 1993) . In order to understand antiapoptotic activity induced by BARF1, the expression of two cellular proteins, c-myc and Bcl-2 expression was analysed. Since c-myc gene expression was dispensable for apoptosis in rodent ®broblasts induced upon serum depletion (Evan et al., 1992) and also down-regulation of c-myc expression level has been observed in EBV positive B lymphocyte cells which present a relative prolongation of cell life span under serum deprivation condition (Ruf et al., 1999) , we initially examined cmyc expression in deletion mutants during exponential growth. Cellular extracts were subjected to analyse the expression of c-myc protein on immunoblot. As demonstrated in Figure 5 , polyclonal rabbit antibody against c-myc (which recognize both human and rodent c-myc) gave an expected 64 kDa of c-myc protein in HL60 cellular extract used as a positive control ( Figure   Figure 5 Western blot analysis of c-myc protein expression. Cellular extracts from culture at 80% con¯uence was electrophoresed and analysed by Western blot with rabbit polyclonal antibody anti-c-myc N-262. HL60 cell line was used as a positive control. c-myc expression was analysed on all transfectants (upper part). b-actin expression was analysed as the loading control using mouse monoclonal anti-b-actin C-2 (lower part) Second, we were interested in the expression of antiapoptotic Bcl-2 gene which has been shown to protect ®broblastic cells from serum deprivation-induced apoptosis (Bissonnette et al., 1992) . Bcl-2 expression in three distinct subclones of each transfectant as well as Balb/c3T3 and Jurkat cells (as a positive control) was analysed using monoclonal mouse antibody against anti-Bcl-2 which recognize both human and rodent Bcl-2 protein. Figure 6 showed a representative immunoblot with anti-Bcl2 antibody. An expected size (25 kDa) of Bcl-2 detectable in Jurkat cells used as a positive control was also found in pZC55, MD3, MD4, MD5 and MD6. The intensity of their bands are almost similar in regard to those of b-actin used as the loading control. However Bcl-2 expression in MD1 and MD2 (lanes 3 and 4) was very faint as those of Balb/ c3T3 cells or pZip-Balb/c3T3 transfectants (lanes 2 and 9). Bcl-2 expression was therefore activated in pZC55, MD3, MD4 and MD5 (Figure 6a, lane 8) . These results suggest that BARF1 gene could activate expression of Bcl-2 and its N-terminal region (codons 1 to 54), deleted in MD1 and MD2 mutants, is likely sucient to activate Bcl-2 expression. To con®rm this, Bcl-2 expression of four MD6 subclones (containing only codons 1 to 56) were isolated and examined ( Figure 6b ). As expected, all MD6 transfectants (lanes 3 to 6) activated the Bcl-2 protein expression at level comparable to that of pZC55 transfectant (lane 1). These results suggest that the resistance to apoptosis induced by serum deprivation in MD3, MD4, MD5, MD6 and pZC55 transfectants may be caused by deregulation of anti-apoptosis Bcl-2 gene expression. Thus the codons 1 to 54 of BARF1 protein are responsible not only for the induction of malignant transformation, but also for the deregulation of Bcl-2.
Discussion
These mutational analyses indicate that at least a region of BARF1 protein is essential for malignant transformation in rodent ®broblasts. Anchorage dependence and tumorigenicity assays in nude mice showed that the codons 1 to 54 of BARF1 protein are closely associated with its oncogenic activity. The induction of tumors was observed with MD3, MD4, MD5, MD6 and a full-length of BARF1 genetransfected cells, while MD1 having deletion codons 1 to 26 gave three small tumors on 12 nude mice and MD2 transfectants having deletion codons 1 to 54 did not give any tumors. On the other hand, MD4 lacking codons 50 to 120 induced most aggressive tumor among other mutants. These data suggest that Nterminal sequence 1 to 49 of BARF1 protein is likely an important region for full transformation activity. Deletion of this region rendered the cells unable not only to form a heap in soft-agar, but also to induce the tumors in nude mice. This result was con®rmed by MD6 transfectants (which contain only codons 1 to 56) which were capable of forming the heaps in soft-agar and of inducing tumors in nude mice, indicating that only this region of BARF1 is likely essential for the induction of tumors. Nevertheless we can state that the tumor induced by MD6 transfectant is smaller than MD3, MD4, MD5 and pZC55. Actually we have no explanation for this phenomenon. Possibly some other regions localized in codons 50 to 221 may be intervening in the induction of aggressive tumors. In fact MD4 induced a tumor as early as after one week and developed an aggressive tumor as those obtained with a full-length of BARF1 gene (pZC55). It is worthy to note that in B cell system, a recombinant EBV with BARF1 deleting the codons 49 to 151 had a capacity to induce a tumor in nude mice similar to B cells containing full BARF1 sequence (Cohen and Lekstrom, 1999) .
A striking observation made in this study is that MD3, MD4, MD5, MD6 and BARF1 transfectants could grow with a similar rate either with 10 or 1% of serum concentration for 16 days and moreover these cells remained living and grew slowly with the concentration of serum as low as 0.1%, while MD1, MD2, Balb/c3T3 and pZip-Balb/c3T3 stopped their growth after 4 days with 10% serum and entered into apoptosis with 1 and 0.1% serum concentration. Thus, the region codons 1 to 54 of BARF1 protein rendered cells resistant to apoptosis. This resistance does not seem to be related to the modi®cation of c-myc gene expression. By contrast, the resistance to apoptosis may come from the activated expression of antiapoptotic Bcl-2 protein. Both BARF1 gene and the deletion mutants (MD3, MD4, MD5 and MD6) were capable of growing under low concentrations of serum, while Balb/c3T3, pZip-Balb/c3T3, MD1 and MD2, all incapable of growing at low serum concentration were not activated Bcl-2 protein. This new ®nding supports a hypothesis that BARF1 may contribute apoptosis resistance under serum deprivation by activating Bcl-2 expression. Since constitutive over-expression of c-myc protein has an ability to induce apoptosis in ®broblasts when deprived of serum (Evan et al., 1992; Wagner et al., 1993) and the apoptosis induced could be blocked by Bcl-2 (Bissonnette et al., 1992; Wagner et al., 1993) , it will be plausible that apoptosis induced by serum deprivation in MD1, MD2 and Balb/c3T3 is an apoptosis mediated by c-myc and this apoptosis could be blocked by Bcl-2 up-regulation induced by the Nterminal codons 1 to 54 region. It is worthy to note that EBV latent LMP1 was not able to activate Bcl-2 protein expression in Balb/c3T3 (Martin et al., 1993) , while LMP1 activated Bcl-2 expression in B cells (Henderson et al., 1991) , suggesting that Bcl2 activation by LMP1 is likely to be cell type speci®c (Rowe et al., 1994) . Immunohistochemical double staining method revealed that the expression of Bcl-2 protein is independent of LMP1 protein expression in NPC epithelial cells (Tao et al., 1994) . In our study, Bcl-2 activation by BARF1 protein was observed not only in Balb/c3T3, but also in BARF1-transfected EBV negative human B cells (Sheng et al., in preparation) as well as in epithelial cells (Cabras et al., in preparation) . This suggests a large tropism of BARF1 to activate Bcl-2 expression in dierent type of cells. BARF1 gene was expressed in more than 90% of nasopharyngeal epithelial tumor cells (Sbih-Lammali et al., 1996; Hayes et al., 1999; Decaussin et al., 2000) . It has been shown that NPC biopsies expressed Bcl-2 protein (Lu et al., 1993) . It is quite possible that BARF1 gene is one of the activators of Bcl-2 expression observed in NPC tumors.
The cooperative action of several oncogenes was essential to passage a cell from benign to malignant state in rodent cells (Land et al., 1983; Reed et al., 1990) . A malignant transformation observed here in Balb/c3T3 transfected by BARF1 gene may come from a cooperation of Bcl-2 with BARF1. Previous data showed that cooperation of Bcl-2 with c-Ha-Ras oncogenes was essential for a malignant transformation of Rat embryo ®broblasts (Reed et al., 1990) , but no malignant transformation was observed on the cooperation with other c-myc or E1A protein (Reed et al., 1990) . In the hematopoietic system, it was also shown that cooperation of BCR ± ABL oncogenes with Bcl-2 expression resulted to prevent apoptotic death in murine hematopoietic cells (Sanchez-Garcia and GruÈ tz, 1995) . This reinforces the idea that a malignant transformation induced by BARF1 in rodent cells is likely to be due to the cooperation between a viral gene and a cellular anti-apoptotic protein. This is a ®rst report on the cooperation of Bcl2 protein with a short EBV amino acid sequence to induce a malignant transformation in rodent cells. This transforming region has some sequence homologies with the immunoglobulin sequences, but no signi®cant homology with known cellular oncogenes.
Our future study will be focussed on the mechanism of Bcl-2 activation by a short amino acid sequence encoded by BARF1 gene.
Materials and methods
Cell culture
Balb/c3T3 cell line was maintained in DMEM (Dulbecco modi®ed Eagle medium) medium (Sigma), and HL60 and EBV carrying P3HR-1 cell lines in RPMI 1640 (Sigma). All mediums were supplemented with 10% fetal bovine serum (Sigma), 120 mg/ml streptomycin (Gibco) and 120 mg/ml penicillin (Gibco) at 378C in a 5% CO2 humidi®ed atmosphere. Lymphoid cells were seeded at 0.5610 6 /ml and harvested after 3 days. P3HR-1 cells were treated for 72 h with 50 ng/ml of 13-0-tetradecanoyl-phorbol-esther (TPA) and 2 mM sodium butyrate (SB) in order to induce a viral lytic cycle (Ooka and Calender, 1980) .
Construction of plasmids containing deletion mutants
Six deletion mutants of dierent BARF1 region were constructed by PCR mutagenesis method (Higuchi, 1990) . For ampli®cation of deletion mutant fragments, the following PCR primer sequences are used to amplify from a full-length of BARF1 gene: For MD1 (deletion at position 165507-165581 of EBV genome, Baer et al., 1984) , 5'-GGGGATC-CAATGGAGCGAGTCACCCTGACCTC-3' (5'-primer) and 5'-GGGGATCCAAGGTGAAATAGGCAAGTGCG-3' (3'-primer). For MD2 (deletion at position 165507-165665), 5'-GGGGATCCAATGGAGGAGCAGGTGCTTATTGGG-3' (5'-primer) and 5'-GGGGATCCAAGGTGAAATAGGCAA-GTGCG-3' (3'-primer).
MD3 (deletion at position 165765 ± 166022) was prepared by using two inside primers and two outside primers as follows: two inside primers are 5'-CACAGAAGTGCCAA-CACCTTCGGTGTTATGAAGGAAAAGGAT-3' (5'-inside primer) and 5'-TCCTTTTCCTTCATAACACCGAAGGTG-TTGGCACTTCTGTG-3' (3'-inside primer); two outside primers are 5'-GGGGATCCCAGAGCAATGGCCAGGT-TC-3' (5'-outside primer) and 5'-GGGGATCCAAGGT-GAAATAGGCAAGTGCG-3' (3'-outside primer). For MD4 (deletion at position 165651 ± 165863), two inside primers are 5'-GAGATTGAGGTCAGCTGGTTTGTGGT-GAAGCCTCTAACGCT-3' (5'-inside primer) and 5'-CAGCGTTAGAGCCTTCACCACAAACCAGCTGACCT-CAATCTC-3' (3'-inside primer); two outside primers are 5'-GGGGATCCCAGAGCAATGGCCAGGTTC-3' (5'-outside primer) and 5'-GGGGATCCAAGGTGAAATAGGCAAG-TGCG-3' (3'-outside primer). For MD5 (deletion at position 166017 ± 166167), 5'-GGGGATCCCAGAGCAATGGCCA-GGTTC-3' (5'-primer) and 5'-GGGGATCCTGCCGCAGT-TGGTGCGGGCTC-3' (3'-primer). For MD6 (deletion at position 165667 ± 166167), A full-length of BARF1 gene cloned in pZip vector was digested by two enzymes Pme1 and PshA1.
A phophorylated oligonucleotide, 5'-AAACTGTAAT-TAATTAATGATCTCAAA-3' containing stop codons in three open reading frames was inserted in the place of Pme1/PshA1 fragment. Ampli®ed fragments with each primer were cloned ®rstly in pBKS plasmid (Pharmacia, France) in order to verify their nucleotide sequence. The mutant BARF1 gene was cut by the treatment of BamH1 restriction enzyme, then inserted into BamH1 site of the pZip-Neo-SV(X) vector containing a neomycin resistance gene (Wei and Ooka, 1989) .
DNA transfection
Plasmid DNA was previously puri®ed twice by CsCl (Cesium Chloride) density gradient centrifugation. Subcon¯uent Balb/ c3T3 cell cultures were transfected with 50 mg of plasmid DNA without carrier by the phosphate technique (Graham and Van der Eb, 1973; Wigler et al., 1979; Shen et al., 1982) . All transfection procedure was already detailed in our previous report (Wei and Ooka, 1989) . At 72 h posttransfection, 500 mg/ml of neomycine (G418, Sigma, France) were added in the medium for selection of drug-resistant cells. Selection mediums were changed every 5 days. G418-resistant cell colonies were formed after 3 ± 4 weeks, isolated with stainless steel cloning cylinders (Bellco Glass, Inc, Vineland NJ, USA) and continued to be cultured.
Oncogene
Growth in soft agar
Anchorage-independent cell growth was assayed in 0.33% soft-agar (Seaplaque, FMC) as already described (Wei and Ooka, 1989) . 0.5610 6 cells were seeded in 4 ml of standard growth medium containing 0.33% low-melting-temperature soft-agar (Sea Kem, FMC Corporation) and plated onto 5 ml layer of solidi®ed 0.66% soft-agar in the same medium in a 100-mm tissue culture dish. Cultures were fed once a week with 1 ml of complete medium. Each cell clone tested was plated in triplicate. The cell colonies becoming visible microscopically after 3 ± 4 weeks were scored weekly and photographed with a Nikon phase-contrast microscope equipped with a camera.
Assays for growth properties
For studies of serum dependence, 0.5610 6 cells were cultured in a 10-mm petri-dish for 24 h in a complete medium with 10% of serum. Cells were then washed twice with serum-free DMEM and transferred to DMEM medium with 10, 1, or 0.1% serum. Each cell line tested was plated in triplicate. The cells were observed daily and fed every 4 days until 16 days. Viability was determined every 4 days, using trypan-blue dye exclusion to monitor cell survival.
Immunoblot analysis
As previously described (Decaussin et al., 1995) , drugresistant cells were collected by centrifuge after twice PBSbuer washing. 1610 7 cells were resuspended in 200 ml NTN buer (100 mM NaCl, 50 mM Tris-HCl pH 8.0, and 0.5% Nonidet P-40) adding a cocktail of anti-protease: 1 mM phenylmethylsurfonyl¯uoride (PMSF), 20 mM (4-aminophenyl)-methanesulfonyl¯uoride (APMSF), 20 mM pepstatin, 10 ml leupeptin, 1 ml aprotinin, 270 mM tosyl lysine chloromethyl ketone (TLCK), and 10 mM benzamidine. Protein concentrations were measured by Bio-Rad protein assay. 40 mg of total cellular protein were mixed with 26sodium dodecyl sulfate (SDS) loading buer (125 mM Tris-Hcl, pH 6.8; 4% SDS; 2 mM DTT; 200 mg/ml glycerol; 0.02 mg/ ml bromophenol bleu). Protein samples were then heated at 1008C for 5 min and electrophoresed on 10% polyacrylamide gel. The proteins were transferred to reinforced nitrocellulose (Schleicher and Schuell) for immunostaining. The blots were incubated 1 h in phosphate-buered saline (PBS) solution with 5% skimmed milk, then incubated overnight with either a monoclonal anti-Bcl-2 (C-2; Santa Cruz) or a polyclonal anti-c-myc (N-262; Santa Cruz) as primary antibodies. The ®lter was then washed with PBS containing 0.1% Tween 20 and incubated for 1 h at room temperature with secondary peroxidase-conjugated anti-mouse (for anti-Bcl2) or antirabbit (for anti-c-myc) antibody. After additional rinse in PBS-0.1% Tween 20 and PBS, the immuno-complexes were visualized by using an enhanced chemiluminescence system (ECL, Amersham).
RT ± PCR
Total RNA was extracted with Tri-reagent (Sigma, France) and treated twice with DNase 1 (Stratagene). Reverse transcriptase PCR (RT ± PCR) was carried out as previously described (Sbih-Lammali et al., 1996) . Five micrograms of total RNA was used for a ®rst-strand cDNA synthesis in a 40 ml reaction volume using oligo(dT)15 as primer. Reverse transcription was done with Superscript Reverse Transcriptase according to instructions of the manufacturer (Gibco, BRL). PCR ampli®cation was performed using the primers as follows: for MD1, MD2, MD5, primers are the same as that used for mutant constructions for MD3 and MD4, primers used are two outside primers as described above.
For MD6, the primers used are 5'-GGGGATCCCAGAG-CAATGGCCAGGTTC-3' and 5'-AAACTGTAATTAAT-TAATGATCTCAAA-3' giving 176 bp of ampli®ed fragment. Ampli®cations were performed in a DNA thermal cycler (Hybaid) as follows: denaturation at 948C for 20 s; annealing at 558C for 30 s and extension at 758C for 1 min. Thirty-®ve cycles were used for ampli®cation. Aliquots of the PCR mixture were subsequently analysed by electrophoresis through a 1% agarose gel followed by Southern transfer onto Hybond N + nylon membranes (Amersham). Detection of ampli®ed BARF1 and its mutant sequences were achieved by hybridization to a 32 P-labeled BARF1 sequence using a random primer DNA labeling kit (Stratagene). The ®lter was hybridized as previously described (Sbih-Lammali et al., 1996) .
Tumorigenicity assays
The cell cultures were incubated till 80% of con¯uence, then the cells were harvested by trypsinization and washed three times in serum-free DMEM, viable cell numbers were determined using a haemocytometer. Cells were resuspended at 10610 6 in 100 ml of DMEM medium without serum and injected subcutaneously into 4 week-old swiss nude mice. Animals were monitored weekly for tumor development.
